Pratz, Keith W <br/><br/>
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Feb 2017 
 - 899-907 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-16-1274  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Benzimidazoles--administration & dosage<br/>Carboplatin--administration & dosage<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug-Related Side Effects and Adverse Reactions--pathology<br/>Fanconi Anemia Complementation Group D2 Protein--genetics<br/>Female<br/>Humans<br/>Leukemia, Biphenotypic, Acute--drug therapy<br/>Leukemia, Myelomonocytic, Chronic--drug therapy<br/>Male<br/>Middle Aged<br/>Myeloproliferative Disorders--drug therapy<br/>Poly (ADP-Ribose) Polymerase-1--antagonists & inhibitors<br/>Topotecan--administration & dosage